WFIP is delighted to announce that INNOVO®, a novel, non-invasive wearable device and electrical muscle stimulator designed to strengthen the pelvic floor, has been approved by the FDA with DeNovo clearance.
This represents a significant milestone for Atlantic Therapeutics. INNOVO® Therapy, is the first transcutaneous electrical stimulation continence device to be cleared by the FDA.

WFIP fully supports this therapy and believes in its potential as an effective proven therapy that can now be offered to help the millions of patients struggling with stress urinary incontinence.

Our thanks to Atlantic Therapeutics for their great efforts and many congratulations from all at WFIP

Please see the press release below:

innovo-press-release_fda_121118